Credit Suisse Starts Ra Pharma (RARX) at Outperform
- Wall St drops as Meta Platforms, economic data weigh
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Dollar firmer on higher U.S. inflation; yen sinks vs euro, US currency
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Jefferies Starts Ra Pharma (RARX) at Buy
November 21, 2016 6:51 AM ESTJefferies initiates coverage on Ra Pharma (NASDAQ: RARX) with a Buy rating and a price target of $25.00.
Analyst Eun Yang commented, "Utilizing its peptide chemistry platform, RARX focus on complement-mediated diseases. Given well-validated C5 target & encouraging Ph1 data, we view lead candidate... More
BMO Capital Starts Ra Pharma (RARX) at Outperform
November 21, 2016 6:44 AM ESTBMO Capital initiates coverage on Ra Pharma (NASDAQ: RARX) with a Outperform rating and a price target of $26.00.
Analyst M. Ian Somaiya commented, " RARX offers investors de-risked access to the multi-billion-dollar complement space, which we believe ALXN has left open to... More